FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 160 filers reported holding FIVE PRIME THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is 1.28 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $5,448,000 | -5.2% | 108,726 | -0.7% | 0.01% | -14.3% |
| Q3 2016 | $5,746,000 | +27.8% | 109,459 | +0.7% | 0.01% | +16.7% |
| Q2 2016 | $4,495,000 | +34.2% | 108,709 | +31.9% | 0.01% | +50.0% |
| Q1 2016 | $3,350,000 | +3.9% | 82,443 | +6.1% | 0.00% | 0.0% |
| Q4 2015 | $3,225,000 | +176.3% | 77,722 | +2.5% | 0.00% | +100.0% |
| Q3 2015 | $1,167,000 | -38.3% | 75,843 | -0.4% | 0.00% | 0.0% |
| Q2 2015 | $1,891,000 | +40.1% | 76,126 | +28.8% | 0.00% | 0.0% |
| Q1 2015 | $1,350,000 | +0.4% | 59,102 | +18.7% | 0.00% | 0.0% |
| Q4 2014 | $1,344,000 | +128.6% | 49,779 | -0.6% | 0.00% | +100.0% |
| Q3 2014 | $588,000 | -23.1% | 50,098 | +1.9% | 0.00% | 0.0% |
| Q2 2014 | $765,000 | +100.8% | 49,174 | +153.4% | 0.00% | 0.0% |
| Q1 2014 | $381,000 | +77.2% | 19,404 | +51.8% | 0.00% | – |
| Q4 2013 | $215,000 | – | 12,786 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eventide Asset Management | 601,000 | $24,587,000 | 1.39% |
| HealthCor Management, L.P. | 1,010,930 | $41,357,000 | 1.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 86,500 | $3,535,000 | 1.38% |
| PURA VIDA INVESTMENTS, LLC | 75,000 | $3,068,000 | 0.90% |
| BB BIOTECH AG | 777,500 | $31,808,000 | 0.88% |
| AWM Investment Company, Inc. | 100,000 | $4,091,000 | 0.71% |
| Granite Point Capital Management, L.P. | 50,000 | $2,046,000 | 0.43% |
| Rock Springs Capital Management LP | 217,700 | $8,906,000 | 0.41% |
| Crestline Management, LP | 50,919 | $2,083,000 | 0.29% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,432,700 | $99,522,000 | 0.24% |